Cipla USA Inc UPS Supply Chain Solu Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Cipla USA Inc UPS Supply Chain Solu Pharmaceutical Import Records from India — 23 Products, $178.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cipla USA Inc UPS Supply Chain Solu — Pharmaceutical Importer Profile (2026) | 23 Products, $178.7M Trade | TransData Nexus

Cipla USA Inc UPS Supply Chain Solu

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $178.7M Total Trade · DGFT Verified

Cipla USA Inc UPS Supply Chain Solu is a pharmaceutical importer based in United States with a total trade value of $178.7M across 23 products in 14 therapeutic categories. Based on 4,676 verified import shipments from Indian Customs (DGFT) records, Cipla USA Inc UPS Supply Chain Solu is the #1 buyer in 5 products including Sertraline, Budesonide, Metoprolol. Cipla USA Inc UPS Supply Chain Solu sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Cipla USA Inc UPS Supply Chain Solu — Import Portfolio & Supplier Network

Cipla USA Inc UPS Supply Chain Solu import network — 23 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cipla USA Inc UPS Supply Chain Solu?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$159.3M	10,000	100.0%

Cipla USA Inc UPS Supply Chain Solu sources from 1 verified Indian supplier across 2,670 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Cipla USA Inc UPS Supply Chain Solu Import?

Formulation	Value	Ships
Albuterol sulfate inhalation aerosol	$11.4M	235
Diclofenac sodium topical gel, 1%w/w	$5.3M	255
Albuterol sulfate inhalation aerosol 90mcg ndc no. 69097-142-60 anda no.	$4.6M	92
Budesonide inhalation suspension	$3.3M	67
Diclofenac sodium topical gel 1%w/w ndc no.69097-524-44 anda no.	$3.2M	157
Metoprolol succinate extended release	$3.2M	68
Arformoterol tartrate inhalation	$3.0M	83
Diclofenac sodium topical gel, 1%w/w	$2.7M	99
Diclofenac sodium topical gel, 1%w/w	$2.5M	128
Albuterol sulfate inhalation aerosol 90mcg ndc no 69097 142 60 anda no 209959 1 x 200	$2.3M	45
Diclofenac sodium topical gel, 1%w/w ndc no.69097-524-44 anda no.	$2.1M	103
Sertraline tablets, USP 100 MG ndc no.	$1.9M	38
Esomeprazole magnesium for delayed	$1.8M	36
Ipratropium bromide and albuterol	$1.8M	50
Diclofenac sodium topical gel 1 w w ndc no 69097 524 44 anda no	$1.6M	77

Import Portfolio — Top 23 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Meloxicam	Analgesics & Antipyretics	$25.3M	533	12.7%	3
2	Amlodipine	Cardiovascular	$22.6M	451	0.2%	5
3	Diclofenac	Analgesics & Antipyretics	$20.5M	990	5.6%	2
4	Sertraline	CNS & Psychiatric	$17.1M	341	3.0%	1
5	Budesonide	Respiratory	$16.6M	331	8.7%	1
6	Metoprolol	Cardiovascular	$12.6M	252	1.6%	1
7	Sodium	Nutritional Supplements	$10.7M	484	3.0%	2
8	Ipratropium	Respiratory	$10.2M	204	17.9%	2
9	Esomeprazole	Gastrointestinal	$7.7M	154	1.7%	3
10	Magnesium	Vitamins & Supplements	$7.7M	154	2.1%	3
11	Formoterol	Respiratory	$6.0M	120	10.5%	2
12	Celecoxib	Analgesics & Antipyretics	$5.7M	165	4.3%	4
13	Fosfomycin	Advanced Antibiotics	$4.8M	96	37.3%	1
14	Omeprazole	Gastrointestinal	$4.0M	81	0.6%	4
15	Fenofibrate	Lipid & Metabolism	$3.2M	234	4.3%	5
16	Fluticasone	Respiratory	$1.3M	25	0.6%	5
17	Darunavir	Antiviral & HIV Medications	$600.0K	12	1.0%	5
18	Cyclophosphamide	Oncology	$500.0K	10	2.6%	1
19	Exemestane	Advanced Oncology	$450.0K	9	3.1%	5
20	Griseofulvin	Advanced Antifungals	$450.0K	9	1.2%	2
21	Emtricitabine	Antiviral & HIV Medications	$350.0K	7	0.3%	11
22	Valacyclovir	Antivirals	$318.3K	9	0.3%	15
23	Efavirenz	Antivirals	$250.0K	5	0.4%	10

Cipla USA Inc UPS Supply Chain Solu imports 23 pharmaceutical products across 14 categories into United States totaling $178.7M. The company is the #1 buyer for 5 products: Sertraline, Budesonide, Metoprolol, Fosfomycin, Cyclophosphamide.

Cipla USA Inc UPS Supply Chain Solu — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cipla USA Inc UPS Supply Chain Solutions is a pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from India. The company operates as a logistics intermediary, facilitating the importation and distribution of pharmaceutical products within the U.S. market. Headquartered at 1920 Outer Loop Road, Louisville, Kentucky 40219, USA, Cipla USA Inc UPS Supply Chain Solutions collaborates closely with its parent company, Cipla Limited, a global pharmaceutical firm established in 1935. This partnership enables the company to leverage Cipla Limited's extensive portfolio and manufacturing capabilities to meet the diverse healthcare needs of the U.S. population. Cipla USA Inc UPS Supply Chain Solutions plays a pivotal role in the U.S. pharmaceutical distribution network by ensuring a steady supply of high-quality, affordable medications sourced from India, thereby enhancing access to essential therapies across the country.

2Distribution Network

Cipla USA Inc UPS Supply Chain Solutions operates a robust distribution network within the United States, with a primary facility located in Louisville, Kentucky. This strategic location facilitates efficient logistics and timely delivery of pharmaceutical products to various regions across the country. The company collaborates with UPS Supply Chain Solutions, a global logistics provider, to manage warehousing, inventory, and distribution processes. UPS Supply Chain Solutions boasts a network of 195 distribution facilities and over 25 million square feet of warehousing and distribution space, ensuring comprehensive coverage and flexibility in meeting the demands of the U.S. pharmaceutical market.

3Industry Role

Cipla USA Inc UPS Supply Chain Solutions functions as a logistics intermediary within the U.S. pharmaceutical supply chain. By importing finished pharmaceutical formulations from India, the company bridges the gap between Indian manufacturers and the U.S. market, ensuring the availability of a wide range of medications. This role is crucial in maintaining a diverse and competitive pharmaceutical landscape in the United States, offering patients access to cost-effective and high-quality therapeutic options.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cipla USA Inc UPS Supply Chain Solu

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cipla USA Inc UPS Supply Chain Solutions demonstrates a high degree of supplier concentration, sourcing 100% of its imported pharmaceutical products from a single supplier, Cipla Limited. This exclusive sourcing strategy indicates a deep-rooted partnership and reliance on Cipla Limited's manufacturing capabilities. While such concentration can lead to favorable terms and streamlined operations, it also presents potential risks, including supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges within the supplier's facilities. The shipment data reveals a consistent and stable relationship, with a total of 4,676 shipments from Cipla Limited, suggesting effective supply chain management and mutual trust. However, the absence of alternative suppliers may limit the company's flexibility in responding to unforeseen disruptions.

2Supply Chain Resilience

The resilience of Cipla USA Inc UPS Supply Chain Solutions' supply chain is closely tied to the stability and reliability of Cipla Limited's operations in India. The company's exclusive sourcing from Cipla Limited indicates a strong dependency on this single supplier, which could pose challenges in the event of supply chain disruptions. The shipment data indicates a consistent flow of products, suggesting effective logistics and inventory management. However, the lack of backup suppliers and limited formulation diversity may expose the company to risks associated with shipping route disruptions, regulatory changes, or operational issues within Cipla Limited's facilities. Ensuring compliance with U.S. Food and Drug Administration (FDA) regulations and maintaining high-quality standards are essential for mitigating potential risks and maintaining supply chain integrity.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and marketing of pharmaceutical products. The FDA enforces stringent regulations to ensure the safety, efficacy, and quality of medications available to the U.S. public. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA) and the Drug Approval Modernization Act, which outline the requirements for drug approval, labeling, and manufacturing practices. For Indian generics to enter the U.S. market, they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug. This pathway ensures that generic medications meet the same standards as their brand-name counterparts, providing patients with safe and effective therapeutic options.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Manufacturers and distributors must register with the FDA and comply with Good Manufacturing Practice (GMP) regulations to ensure product quality and safety. The FDA recognizes GMP certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications facilitate the acceptance of foreign pharmaceutical products in the U.S. market, provided they meet the FDA's standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products, ensuring compliance with federal and state regulations.

Cipla USA Inc UPS Supply Chain Solu — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cipla USA Inc UPS Supply Chain Solutions focuses on importing pharmaceutical products across 14 therapeutic categories, with a significant emphasis on Analgesics & Antipyretics (28.8%), Cardiovascular (19.7%), and Respiratory (19.0%). The top five imported products include Sertraline, Budesonide, Metoprolol, Fosfomycin, and Cyclophosphamide, indicating a strategic focus on medications for mental health, respiratory conditions, cardiovascular diseases, and oncology. This product strategy aligns with market demand for treatments in these therapeutic areas, addressing prevalent health concerns and offering patients access to essential therapies.

2Sourcing Profile

Cipla USA Inc UPS Supply Chain Solutions employs a sourcing strategy centered on generic drugs, primarily sourcing finished pharmaceutical formulations from India. The company's exclusive reliance on Cipla Limited for its imports suggests a strategic choice to leverage the supplier's manufacturing capabilities and product portfolio. This approach allows for streamlined operations and potentially favorable terms but also exposes the company to risks associated with supplier dependency. India's established pharmaceutical manufacturing industry, recognized for its adherence to international quality standards, positions it as a key player in Cipla USA Inc UPS Supply Chain Solutions' overall procurement strategy.

Market Positioning

Seller's Guide — How to Become a Supplier to Cipla USA Inc UPS Supply Chain Solu

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Cipla USA Inc UPS Supply Chain Solutions, particularly in therapeutic areas where the company seeks to expand its product offerings. Identifying gaps in the current sourcing strategy, such as unmet needs in specific therapeutic categories or formulations, can provide avenues for new suppliers to enter the market. Establishing robust quality assurance processes, ensuring compliance with FDA regulations, and demonstrating the ability to meet market demand are essential for gaining acceptance and building a successful partnership.

2Requirements & Qualifications

Indian exporters aiming to supply Cipla USA Inc UPS Supply Chain Solutions and the

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Cipla USA Inc UPS Supply Chain Solu

What products does Cipla USA Inc UPS Supply Chain Solu import from India?

Cipla USA Inc UPS Supply Chain Solu imports 23 pharmaceutical products across 14 categories. Top imports: Meloxicam ($25.3M), Amlodipine ($22.6M), Diclofenac ($20.5M), Sertraline ($17.1M), Budesonide ($16.6M).

Who supplies pharmaceuticals to Cipla USA Inc UPS Supply Chain Solu from India?

Cipla USA Inc UPS Supply Chain Solu sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $159.3M).

What is Cipla USA Inc UPS Supply Chain Solu's total pharmaceutical import value?

Cipla USA Inc UPS Supply Chain Solu's total pharmaceutical import value from India is $178.7M, based on 4,676 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cipla USA Inc UPS Supply Chain Solu focus on?

Cipla USA Inc UPS Supply Chain Solu imports across 14 categories. The largest: Analgesics & Antipyretics (28.8%), Cardiovascular (19.7%), Respiratory (19.0%).

Get Full Cipla USA Inc UPS Supply Chain Solu Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.